Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
Trial details
- Registry ID
- NCT07363577
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as LB-102
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute SchizophreniaNCT07363577 | LBRX | Phase 3 | Recruiting | 2027-06Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |